The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1393
June 25, 2012
View Complete Issue         Table of Contents 2019 
Bisphosphonates - Duration of Use Revisited
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Bisphosphonates - Duration of Use Revisited
June 25, 2012 (Issue: 1393)
Long-term use of bisphosphonates for prevention and treatment of osteoporosis has been associated with osteonecrosis of the jaw, atypical fractures of the femur, and possibly esophageal cancer. So for how long should patients take them?
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Bisphosphonates - Duration of Use Revisited
Article code: 1393a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.